Browse News
Filter News
Found 808,346 articles
-
Read the latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
-
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
4/17/2024
Sound Bioventures announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic viral therapies.
-
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
4/17/2024
Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, announced it has successfully closed its latest financing round, raising a total of £19M with the addition of Sound Bioventures as a new investor.
-
Q1 2024 Revenue and Business Update
4/17/2024
Telix Pharmaceuticals Limited provides an update on its revenue and operational performance for the quarter ended 31 March 2024.
-
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
4/17/2024
Orexo AB, announces that the United States Patent and Trademark Office has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
-
SCG Cell Therapy and A*STAR Launch Joint Labs With Collaboration Nearing S$30 Million to Advance iPSC Technology Towards Scalable GMP Manufacturing of Cellular Immunotherapies
4/17/2024
SCG Cell Therapy and the Agency for Science, Technology and Research announced the launch joint laboratories for cellular immunotherapies.
-
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
4/17/2024
Essential Pharma announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
-
Evotec welcomes Aurélie Dalbiez as Chief People Officer
4/17/2024
Evotec SE announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer, effective 15 June 2024.
-
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
4/17/2024
Novartis announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® treatment for up to six years in recently diagnosed – defined as starting treatment within three years of initial diagnosis – treatment-naïve people living with relapsing multiple sclerosis.
-
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
4/17/2024
TScan Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasdaq Global Market on April 16, 2024.
-
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
4/17/2024
Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.
-
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
4/17/2024
Genentech, a member of the Roche Group, announced data from the Phase III OCARINA II study of Ocrevus®, an investigational twice-yearly, 10-minute subcutaneous injection.
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
4/17/2024
BioCryst Pharmaceuticals, Inc. announced that the Brazilian Health Regulatory Agency has granted approval for oral, once-daily ORLADEYO® for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older.
-
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
4/17/2024
Nxera Pharma Co. Ltd announces that it has decided to issue new shares under the 19th to 22nd Restricted Stock Unit Plan and determined the payment amount and other matters of issuance of new shares under the 12th RSU and 14th RSU as follows.
-
Despite the strong performance of its cancer portfolio, Johnson & Johnson on Tuesday reported Stelara sales of $2.45 billion in the first quarter of 2024, falling short of Wall Street expectations of $2.6 billion.
-
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
-
The German biopharma company on Tuesday announced ambitious pipeline plans that include starting 10 new Phase II and III trials over the next 12 to 18 months.
-
Novartis on Monday shared late-stage data for its potential multibillion-dollar drug Fabhalta, in what the company contends is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in IgA nephropathy patients.
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
In a Phase I/II study, Ultragenyx’s antisense oligonucleotide GTX-102 led to significant cognitive, behavioral, sleep and gross motor improvements in patients with the rare genetic disorder Angelman syndrome.